Payment overview · 2025
General Payments
$74,596.24
299 reported records · 22 companies
Healthcare provider profile · identity verified
George S Chrysant, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · OKLAHOMA CITY, OK · NPI 1093719015
Verified facts
What the public records show
CMS Open Payments records show George S Chrysant, MD received $74,596.24 in general payments during 2025 across 299 reported records.
Penumbra, Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $25,278.62 | 33.9% | 34 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $16,546.70 | 22.2% | 33 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $9,252.41 | 12.4% | 33 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $8,443.18 | 11.3% | 67 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$7,649.92 | 10.3% | 71 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $3,555.36 | 4.8% | 19 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,890.55 | 2.5% | 13 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $920.20 | 1.2% | 9 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $277.83 | 0.4% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $203.84 | 0.3% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $125.78 | 0.2% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $97.25 | 0.1% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $65.82 | 0.1% | 3 | 2025 |
| Acarix USA Inc. | Unresolved — no canonical attribution shown | $54.00 | 0.1% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $53.85 | 0.1% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $37.50 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $35.56 | 0.1% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $28.78 | 0.0% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $23.07 | 0.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $21.46 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.56 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $23,912.50 | 11 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,512.50 | 8 |
| Food and Beverage | $11,635.61 | 248 |
| Travel and Lodging | $10,135.63 | 30 |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,400.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $25,023.12 | 31 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $12,600.00 | 5 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $9,085.93 | 31 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $7,942.56 | 11 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $7,212.92 | 65 | 2025 |
Source payment records
|
|||||
| PROSTAR Normalized: prostar |
Device | Abbott Laboratories | $3,029.39 | 14 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $2,729.62 | 16 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $1,277.16 | 6 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $1,217.08 | 12 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $920.20 | 9 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $397.05 | 5 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $348.02 | 4 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $255.50 | 3 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $203.84 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $191.60 | 16 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $177.95 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $142.84 | 15 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $125.78 | 2 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $119.05 | 19 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $97.25 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc., Becton, Dickinson and Company | $88.89 | 4 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $65.84 | 1 | 2025 |
Source payment records
|
|||||
| CADScor System Normalized: cadscor system |
Device | Acarix USA Inc. | $54.00 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $53.85 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $39.95 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $37.50 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $35.56 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $35.56 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Large Access Solution Normalized: versacross large access solution |
Device | Boston Scientific Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $10.76 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $8.40 | 2 | 2025 |
Source payment records
|
|||||
| NRG Transseptal Needle Normalized: nrg transseptal needle |
Device | Boston Scientific Corporation | $7.82 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $5.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 249 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 157 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 24 |
| Carvedilol | Carvedilol | 97 | 20 |
| Eliquis | Apixaban | 91 | 20 |
| Lisinopril | Lisinopril | 86 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 28 |
| Furosemide | Furosemide | 76 | 18 |
| Losartan Potassium | Losartan Potassium | 67 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Prednisone | Prednisone | 19 | 13 |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74,596.24 · 299 records | Penumbra, Inc. | ATRICLIP LAA EXCLUSION SYSTEM, AVVIGO Guidance System, Assure WCD, CADScor System, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, Cleerly Ischemia, Cleerly Labs, Coronary Other, Coronary Undivided, ESPRIT, EVOQUE, FARAPULSE, FFRct, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GORE VIABAHN Endoprosthesis, General - Therapies, IGT Devices Undivided, Indigo System, LifeVest, NRG Transseptal Needle, Nimbl, ONYX FRONTIER, PASCAL, PROSTAR, Paradise Ultrasound Renal Denervation System, Penumbra System, RADIAL 360, SUPERA, SYMPLICITY G3, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Venclose Maven Catheter, VersaCross Access Solution, VersaCross Large Access Solution, WATCHMAN, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error